Study S001092

Phase I Study of ALT-801 in Patients With Progressive Metastatic Malignancies

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT00496860
Study type: INTERVENTIONAL
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 26
Start: 2007-05
Primary completion: 2009-10
Lead sponsor: Altor BioScience
Conditions: Progressive Metastatic Malignancies
Interventions: BIOLOGICAL:ALT-801
Results posted: TRUE

Registered primary outcomes

The Safety and Toxicity of ALT-801 in Patients With Progressive Metastatic Malignancies [18 months]
The Maximum-tolerated Dose (MTD) of ALT-801 [18 months]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025060	Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Fishman MN, Clinical cancer research : an official journal of the American Association for Cancer Research	2011	Nonrandomized study	PMID 21994418 DOI	cites ClinicalTrials.gov:NCT00496860; registry reference DERIVED:21994418